These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 25306106

  • 1. ¹⁸F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients.
    Jiménez Londoño GA, García Vicente AM, Sánchez Pérez V, Jiménez Aragón F, León Martin A, Cano Cano JM, Domínguez Ferreras E, Gómez López OV, Espinosa Arranz J, Soriano Castrejón ÁM.
    Eur J Radiol; 2014 Dec; 83(12):2224-2230. PubMed ID: 25306106
    [Abstract] [Full Text] [Related]

  • 2. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E, Soydal C, Araz M, Aras G.
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [Abstract] [Full Text] [Related]

  • 3. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y, Kitajima K, Ishihara T, Sasaki R, Otsuki N, Nibu K, Minamikawa T, Kiyota N, Sugimura K.
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [Abstract] [Full Text] [Related]

  • 4. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E, Soydal C, Araz M, Kir KM, Ibis E.
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic accuracy of F-18 FDG PET/CECT vs. CECT for detecting recurrence of periampullary carcinoma and its prognostic significance.
    Santhosh S, Mittal BR, Kang M, Kapoor R, Gupta R, Rana S, Bhattacharya A, Bhasin D.
    Abdom Imaging; 2015 Jun; 40(5):1131-7. PubMed ID: 25655637
    [Abstract] [Full Text] [Related]

  • 6. The impact of 18F-FDG PET/CT in patients with liver metastases.
    Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, Bomanji JB, Ell PJ.
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1906-14. PubMed ID: 17713766
    [Abstract] [Full Text] [Related]

  • 7. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET.
    García Vicente AM, Domínguez Ferreras E, Sánchez Pérez V, Poblete García VM, Villa Guzmán JC, Jiménez Aragón F, Pineda Pineda MD, Molino Trinidad C, Soriano Castrejón Á.
    Eur J Radiol; 2013 Jun; 82(6):e255-61. PubMed ID: 23414715
    [Abstract] [Full Text] [Related]

  • 8. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E, Datseris IE, Rondogianni P, Vlontzou E, Skilakaki M, Exarhos D, Bamias A.
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [Abstract] [Full Text] [Related]

  • 9. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C, Buecher B, Rousseau C, Kraeber-Bodéré F, Flamant M, des Varannes SB, Frampas E, Galmiche JP, Matysiak-Budnik T.
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [Abstract] [Full Text] [Related]

  • 10. Detection of recurrent colorectal cancer by 18F-FDG PET/CT comparison with contrast enhanced CT scan.
    Chiewvit S, Jiranantanakorn T, Apisarnthanarak P, Kanchaanapiboon P, Hannanthawiwat C, Ubolnuch K, Phongsawat N, Chiewvit P.
    J Med Assoc Thai; 2013 Jun; 96(6):703-8. PubMed ID: 23951828
    [Abstract] [Full Text] [Related]

  • 11. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V, Odalovic S, Sobic-Saranovic D, Petrovic M, Stojiljkovic M, Petrovic N, Kozarevic N, Grozdic-Milojevic I, Obradovic V.
    Hell J Nucl Med; 2015 Jun; 18(1):35-41. PubMed ID: 25840571
    [Abstract] [Full Text] [Related]

  • 12. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD, Veit-Haibach P, Strobel K, Breitenstein S, Tschopp A, Mende KA, Lago MP, Hany TF.
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [Abstract] [Full Text] [Related]

  • 13. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG, Gerke O, Baun C, Falch K, Hansen JA, Farahani ZA, Petersen H, Larsen LB, Duvnjak S, Buskevica I, Bektas S, Søe K, Jylling AM, Ewertz M, Alavi A, Høilund-Carlsen PF.
    J Clin Oncol; 2016 Jun 01; 34(16):1889-97. PubMed ID: 27001573
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A, Niccoli Asabella A, Coppolino P, Quartuccio N, Altini C, Cucinotta M, Alongi P, Balma M, Sanfilippo S, Buschiazzo A, Piccardo A, Fanelli M, Sambuceti G, Bomanji J, Baldari S, Bisi G, Fanti S, Rubini G.
    Hell J Nucl Med; 2015 Jun 01; 18(2):97-102. PubMed ID: 26187207
    [Abstract] [Full Text] [Related]

  • 15. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O, Kaya B, Kara PO, Gedik GK, Celik C, Ozbek O, Serdengecti M.
    Rev Esp Med Nucl Imagen Mol; 2012 Jun 01; 31(1):3-8. PubMed ID: 21549452
    [Abstract] [Full Text] [Related]

  • 16. The value of (18) F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction.
    Müller J, Hüllner M, Strobel K, Huber GF, Burger IA, Haerle SK.
    Laryngoscope; 2015 Aug 01; 125(8):1861-8. PubMed ID: 25892275
    [Abstract] [Full Text] [Related]

  • 17. [Diagnostic value of ¹⁸F-fluorodexyglucose positron emission tomography combined with contrast enhanced computed tomography in colorectal cancer liver metastasis].
    Zhang Z, Lyu Q, Chen F, Liao S, Zhang J, Hu R, Hu P.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Mar 01; 18(3):238-42. PubMed ID: 25809326
    [Abstract] [Full Text] [Related]

  • 18. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P.
    Abdom Radiol (NY); 2018 Feb 01; 43(2):505-513. PubMed ID: 28900703
    [Abstract] [Full Text] [Related]

  • 19. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
    Niccoli-Asabella A, Altini C, Notaristefano A, Merenda N, Altieri ML, Stabile-Ianora AA, Fanelli M, Rubini G.
    Nucl Med Commun; 2013 Jan 01; 34(1):32-9. PubMed ID: 23111380
    [Abstract] [Full Text] [Related]

  • 20. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
    D'souza MM, Sharma R, Mondal A, Jaimini A, Tripathi M, Saw SK, Singh D, Mishra A, Tripathi RP.
    Nucl Med Commun; 2009 Feb 01; 30(2):117-25. PubMed ID: 19057427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.